1. Home
  2. WVE vs PCN Comparison

WVE vs PCN Comparison

Compare WVE & PCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

BUY

Current Price

$3.45

Market Cap

744.8M

Sector

Health Care

ML Signal

BUY

Logo Pimco Corporate & Income Strategy Fund

PCN

Pimco Corporate & Income Strategy Fund

HOLD

Current Price

$10.76

Market Cap

805.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
WVE
PCN
Founded
2012
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
744.8M
805.4M
IPO Year
2015
2001

Fundamental Metrics

Financial Performance
Metric
WVE
PCN
Price
$3.45
$10.76
Analyst Decision
Strong Buy
Analyst Count
19
0
Target Price
★ $18.06
N/A
AVG Volume (30 Days)
★ 2.9M
619.4K
Earning Date
11-09-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $3,704,000.00
N/A
Revenue This Year
$19.21
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 149.43
N/A
52 Week Low
$3.43
$10.44
52 Week High
$21.73
$13.47

Technical Indicators

Market Signals
Indicator
WVE
PCN
Relative Strength Index (RSI) 25.92 38.75
Support Level N/A N/A
Resistance Level $6.33 $11.98
Average True Range (ATR) 0.23 0.20
MACD -0.02 0.01
Stochastic Oscillator 8.56 39.75

Price Performance

Historical Comparison
WVE
PCN

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About PCN Pimco Corporate & Income Strategy Fund

PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.

Share on Social Networks: